DARZALEX 20 mg/mL concentrate for solution for infusion.

*
Pharmacy Only: Prescription

Updated on 24 October 2024

File name

EN-IE-Darzalex IV-20241021-PIL-II-072-clean-approved_EDMS-ERI-78724632_104.0.pdf

Reasons for updating

  • Change to section 6 - date of revision

Free text change information supplied by the pharmaceutical company

EMEA/H/C/004077/II/0072: Type II variation, indication extension (D-VRd in NDMM) based on the PERSEUS study. The indication extension impacted the SC formulation only but there was a small administrative update to the PIL for the IV formulation; at the end of the document the EMA website address was changed from: http://www.ema.europa.eu to https://www.ema.europa.eu. The date of revision was also updated.

Updated on 16 October 2024

File name

EN-IE-Darzalex IV-20240919-SmPC-II-074-clean-approved_EDMS-ERI-78724632_102.0.pdf

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

EMEA/H/C/004077/II/0074: Provision of the final CSR of study MMY3008 (MAIA)

Updated on 20 March 2024

File name

EN-Darzalex IV-20240215-SPC-II-070-clean-approved_EDMS-RIM-1256104_2.0.pdf

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

II/070: CCDS update MMY3007 Final OS analysis 

Updated on 15 November 2023

File name

SPC-Darzalex_IE-UK(NI)_EN_Type IB_069_IV Formulation 20mg-mL_20mL and 5mL_Shelf Life Extension_Clean.pdf

Reasons for updating

  • Change to section 6.3 - Shelf life
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

6.3    Shelf life

 Unopened vials

 23 years.

10.    DATE OF REVISION OF THE TEXT

 14 November 2023


Updated on 03 November 2023

File name

Clean EN-PIL-IE -IV 20mg MI and Ocular Darzalex with GEN 2 -049.pdf

Reasons for updating

  • Change to section 2 - excipient warnings
  • Change to section 6 - what the product contains

Updated on 03 November 2023

File name

Clean SmPC IE 20mg IV MI and Ocular with GEN 2-049-.pdf

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 6.1 - List of excipients

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 24 March 2023

File name

EN-IE -IV 20mg MI and Ocular Darzalex-20230209-II-063-064-clean-adjusted-without-II-049 .pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects

Free text change information supplied by the pharmaceutical company

Updated to add Myocardial Infarction and Ocular events as signs/symptoms of Infusion Related Reactions.


Updated on 24 March 2023

File name

SmPC 20mg IV MI and Ocular EN-Darzalex-20230209-063-064-clean-adjusted-without-II-049.pdf

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Updated to add Myocardial Infarction and Ocular events as signs/symptoms of Infusion Related Reactions.

  • SmPC Section 4.4 and 4.8 impacted. 


Updated on 16 January 2023

File name

IE_NI - SPC IV - Addition of COVID-19 as an ADR.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 16 January 2023

File name

IE_NI-Patient Information Leaflet IV - Addition of COVID-19 as an ADR.pdf

Reasons for updating

  • Change to section 4 - possible side effects

Updated on 25 July 2022

File name

Darzalex IV - consolidated changes from 060 and 061.pdf

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

EMA/H/C/4077/II/060/G - Final OS data from studies MMY3003 and MMY3004 resulting in update to section 5.1

EMEA/H/C/004077/IB/061/G - CMC - ATC code + shelf life SC to 2 years - resulting in update to Section 5.1 and Section 6.3 (SC formulation only)

EDM Updated on 09 June 2022

File name

Clean Darzalex RMP HCP Card black triangle update.pdf

Reasons for updating

  • Replace File

Free text change information supplied by the pharmaceutical company

Removal of Black Triangle

EDM Updated on 09 June 2022

File name

Clean Patient Card - Darzalex black triangle update.pdf

Reasons for updating

  • Replace File

Free text change information supplied by the pharmaceutical company

Removal of Black Triangle

EDM Updated on 09 June 2022

File name

Clean Darzalex RMP Blood Lab Card - black triangle update.pdf

Reasons for updating

  • Replace File

Free text change information supplied by the pharmaceutical company

Removal of Black Triangle

Updated on 25 March 2022

File name

IV Adjusted version - EN-Darzalex-IB-057-approved with II_53 revisions shown Clean.pdf

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Inclusion of updated efficacy data from Study MMY3008 in section 5.1 of the SmPC

Updated on 12 January 2022

File name

IE_NI-PIL-20 mg _mL_PIL - Jan 22 - EUPI-R-054-approved-adjusted-without-II-049.pdf

Reasons for updating

  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 6 - date of revision
  • Removal of Black Inverted Triangle

Free text change information supplied by the pharmaceutical company

Black triangle and explanatory text were removed from the SmPC and patient leaflet. QRD changes were made where applicable throughout the SmPC and patient leaflet

Updated on 12 January 2022

File name

IE_NI - 20 mg per ml - Jan 22 - EUPI-R-054-approved-adjusted-without-II-049.pdf

Reasons for updating

  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 9 - Date of first authorisation/renewal of the authorisation
  • Change to section 10 - Date of revision of the text
  • Removal of Black Inverted Triangle
  • Change to improve clarity and readability

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Black triangle and explanatory text were removed from the SmPC and patient leaflet. QRD changes were made where applicable throughout the SmPC and patient leaflet.

EDM Updated on 08 December 2021

File name

Darzalex Patient Card CP-Updated.pdf

Reasons for updating

  • Replace File

Free text change information supplied by the pharmaceutical company

Addition of AL amyloidosis

EDM Updated on 08 December 2021

File name

Darzalex Blood Bank Card CP-Updated.pdf

Reasons for updating

  • Replace File

Free text change information supplied by the pharmaceutical company

Addition of AL amyloidosis

EDM Updated on 08 December 2021

File name

Darzalex HCP Card CP-Updated.pdf

Reasons for updating

  • Replace File

Free text change information supplied by the pharmaceutical company

Addition of AL amyloidosis

Updated on 10 November 2021

File name

IRE & NI Darzalex-20 mg _mL_PIL- C15-050-051-CLEAN-adjusted-without-II-049.pdf

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 10 November 2021

File name

IE&NI_Darzalex 20 mg per mL SmPC C18-050-051-CLEAN-adjusted-without-II-049-07Oct21.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.8          Undesirable effects

 

Immune system disorders

Hypogammaglobulinemiaa

Common

3

<1*

Anaphylactic reactionb

Rare

-

-

 

 

5.1       Pharmacodynamic properties

With a median follow-up of 18.8 months, the primary analysis of PFS Results of a PFS analysis by censoring patients who were randomised to daratumumab maintenance in the second randomisation, at the date of the second randomisation showed HR=0.50; 95% CI: 0.34, 0.75; p=0.0005. Results of an updated PFS analysis with a median follow-up of 44.5 months, censoring patients who were randomised to daratumumab maintenance in the second randomisation, showed HR=0.43; 95% CI: 0.33, 0.55; p<0.0001. Median PFS was not reached in the D‑VTd arm and was 37.8 months in the VTd arm.

Updated on 28 June 2021

File name

IRE & NI Darzalex-20 mg _mL_PIL- C14_21June21_clean.pdf

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 24 June 2021

File name

IE&NI_Darzalex 20 mg per mL SmPC C17-43-44-clean-21June21.pdf

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Free text change information supplied by the pharmaceutical company

fainting added as common side effect

Updated on 24 June 2021

File name

IE&NI_Darzalex 20 mg per mL SmPC C17-43-44-clean-21June21.pdf

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

.2       Posology and method of administration

 

 

Table 1:      DARZALEX dosing schedule in combination with lenalidomide and dexamethasone (Rd) (4-week cycle dosing regimen) and monotherapy

Weeks

Schedule

Weeks 1 to 8

weekly (total of 8 doses)

Weeks 9 to 24a

every two weeks (total of 8 doses)

Week 25 onwards until disease progressionb

every four weeks

a    First dose of the every-2-week dosing schedule is given at Week 9

b    First dose of the every-4-week dosing schedule is given at Week 25

 

Dexamethasone should be administered at 40 mg/week (or a reduced dose of 20 mg/week for patients >75 years).

 

 

Table 3:      DARZALEX dosing schedule in combination with bortezomib, thalidomide and dexamethasone ([VTd]; 4-week cycle dosing regimen)

Treatment phase

Weeks

Schedule

Induction

Weeks 1 to 8

weekly (total of 8 doses)

Weeks 9 to 16a

every two weeks (total of 4 doses)

Stop for high dose chemotherapy and ASCT

Consolidation

Weeks 1 to 8b

every two weeks (total of 4 doses)

a       First dose of the every-2-week dosing schedule is given at Week 9

b      First dose of the every-2-week dosing schedule is given at Week 1 upon re-initiation of treatment following ASCT

 

Dexamethasone should be administered at 40 mg on Days 1, 2, 8, 9, 15, 16, 22 and 23 of Cycles 1 and 2, and at 40 mg on Days 1-2 and 20 mg on subsequent dosing days (Days 8, 9, 15, 16) of Cycles 3-4. Dexamethasone 20 mg should be administered on Days 1, 2, 8, 9, 15, 16 in Cycles 5 and 6.

 

Table 4:      DARZALEX dosing schedule in combination with bortezomib and dexamethasone (Vd) (3-week cycle dosing regimen)

Weeks

Schedule

Weeks 1 to 9

weekly (total of 9 doses)

Weeks 10 to 24a

every three weeks (total of 5 doses)

Week 25 onwards until disease progressionb

every four weeks

a    First dose of the every-3-week dosing schedule is given at Week 10

b       First dose of the every-4-week dosing schedule is given at Week 25

 

Dexamethasone should be administered at 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 bortezomib treatment cycles or a reduced dose of 20 mg/week for patients >75 years, underweight (BMI <18.5), poorly controlled diabetes mellitus or prior intolerance to steroid therapy.

 

4.8     Undesirable effects

Table 6:      Adverse reactions in multiple myeloma patients treated with DARZALEX 16 mg/kg

System Organ Class

Adverse reaction

Frequency

Incidence (%)

Any Grade

Grade 3‑4

Infections and infestations

PneumoniaaUpper respiratory tract infectiona

Very Common

1641

103

Bronchitisa

17

2

Upper respiratory tract infectionaPneumoniaa

4116

310

Urinary tract infection

Common

8

1

Influenza

5

1*

Sepsisa

4

4

Cytomegalovirus infectiona

1

<1*

Hepatitis B Virus reactivationb

Uncommon

-

-

Blood and lymphatic system disorders

Neutropeniaa

Very Common

44

39

Thrombocytopeniaa

31

19

Anaemiaa

27

12

Lymphopeniaa

14

11

Leukopeniaa

12

6

Immune system disorders

Anaphylactic reactionb

Rare

-

-

Metabolism and nutrition disorders

Decreased appetite

Very Common

12

1

Hyperglycaemia

Common

7

3

Hypocalcaemia

6

1

Dehydration

3

1*

Nervous system disorders

Peripheral sensory neuropathy

Very Common

 

32

3

ParaesthesiaHeadache

1112

<1*

HeadacheParaesthesia

1211

<1*

Syncope

Common

2

2*

Cardiac disorders

Atrial fibrillation

Common

4

1

Vascular disorders

Hypertensiona

Very Common

10

5

Respiratory, thoracic and mediastinal disorders

Cougha

Very Common

25

<1*

Dyspnoeaa

21

3

Pulmonary oedemaa

Common

1

<1

Gastrointestinal disorders

DiarrhoeaConstipation

Very Common

3233

41

ConstipationDiarrhoea

3332

14

Nausea

26

2*

Vomiting

16

1*

Pancreatitisa

Common

1

1

Musculoskeletal and connective tissue disorders

Back pain

Very Common

18

2

Muscle spasms

14

<1*

General disorders and administration site conditions

Fatigue

Very Common

26

4

Oedema peripherala

26

1

Pyrexia

23

2

Asthenia

21

2

Chills

Common

9

<1*

Injury, poisoning and procedural complications

Infusion‑related reactionc

Very Common

40

4

*   No Grade 4

a    Indicates grouping of terms

b    Post‑marketing adverse reaction

c    Infusion-related reaction includes terms determined by investigators to be related to infusion, see below

 

Updated on 17 June 2021

File name

IRE & NI Darzalex-20 mg _mL_PIL- C13 20 May 21-Clean.pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions

Free text change information supplied by the pharmaceutical company

Infusion‑related reactions

DARZALEX is given as an infusion (drip) into a vein. Before and after each infusion of DARZALEX, you will be given medicines which help to lower the chance of infusion‑related reactions (see “Medicines given during treatment with DARZALEX” in section 3). These reactions can happen during the infusion or in the 3 days after the infusion.

In some cases you may have a severe allergic reaction which may include a swollen face, lips, mouth, tongue or throat, difficulty swallowing or breathing or an itchy rash (hives). Some serious allergic reactions and other severe infusion-related reactions have resulted in death.

Updated on 17 June 2021

File name

IE&NI_Darzalex 20 mg per mL IV- SmPC C16-047_CLEAN .pdf

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.4       Special warnings and precautions for use

 

Traceability

In order to improve the traceability of biological medicinal products, the tradename and the batch number of the administered product should be clearly recorded.

 

Infusion‑related reactions

DARZALEX can cause serious IRRs, including anaphylactic reactions (see section 4.8). These reactions can be life-threatening and fatal outcomes have been reported.

 

Section 4.8

 

Infections

In patients receiving DARZALEX combination therapy, Grade 3 or 4 infections were reported as follows:

Relapsed/refractory patient studies: DVd: 21%, Vd: 19%; DRd: 287%, Rd: 23%; DPd: 28%

Newly diagnosed patient studies: D‑VMP: 23%, VMP: 15%; DRd: 32%, Rd: 23%; D-VTd: 22%, VTd: 20%.

Updated on 13 January 2021

File name

IRE Darzalex-20 mg _mL_PIL- C12 03 Dec 2020-041-Clean.pdf

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 13 January 2021

File name

Darzalex 20 mg per mL IV- SmPC C15-041-Clean-approved.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.8 Undesirable effects

Infections and infestations

Pneumoniaa

Very Common

16

10

Bronchitisa

17

2

Upper respiratory tract infectiona

41

3

Urinary tract infection

Common

8

1

Influenza

5

1*

Sepsisa

4

4

Cytomegalovirus infectiona

1

<1*

Hepatitis B Virus reactivationb

Uncommon

-

-

Updated on 20 August 2020

File name

IRE Darzalex-20 mg per mL PIL- C11- 20 Jan 2020-038-Clean-approved.pdf

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 20 August 2020

File name

Darzalex 20 mg per mL IV- SmPC C14-038-Clean-approved.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.8     Undesirable effects

 

Summary of the safety profile

The most frequent adverse reactions of any grade (≥20 % patients) with daratumumab (either intravenous or subcutaneous formulations) when administered either as monotherapy or combination treatment were IRRs, fatigue, nausea, diarrhoea, constipation, pyrexia, cough, neutropenia, thrombocytopenia, anaemia, oedema peripheral, peripheral sensory neuropathy and upper respiratory tract infection. Serious adverse reactions were pneumonia, bronchitis, upper respiratory tract infection, sepsis, pulmonary oedema, influenza, pyrexia, dehydration, diarrhoea and atrial fibrillation.

 

…………………

 

System Organ Class

Adverse reaction

Frequency

Incidence (%)

Any Grade

Grade 3-4

Infections and infestations

Upper respiratory tract infectiona

Very Common

38%

2%

Bronchitisa

Very Common

14%

2%

Pneumoniaa

Very Common

14%

9%

Urinary tract infection

Common

7%

1%

Influenza

Common

4%

1%#

Sepsisa

Common

4%

3%

 

 

………………………..

 

Infections

In patients receiving DARZALEX subcutaneous formulation as monotherapy, incidence of infections was similar between DARZALEX subcutaneous formulation (52.9%) versus intravenous daratumumab groups (50.0%). Additionally, Grade 3 or 4 infections also occurred at similar frequencies between DARZALEX subcutaneous formulation (11.7%) and intravenous daratumumab (14.3%). Most infections were manageable and rarely led to treatment discontinuation. Pneumonia was the most commonly reported severe (Grade 3 or 4) infection across studies.

 

In patients receiving intravenous daratumumab combination therapy, Grade 3 or 4 infections were reported with intravenous daratumumab combinations and background therapies (as follows:

Relapsed/refractory patient studies: DVd: 21%, Vd: 19%; DRd: 27%, Rd: 23%; D‑VMP: 23%, VMP: 15%; DPd: 28%

Newly diagnosed patient studies: D‑VMP: 23%, VMP: 15%; DRd: 32%, Rd: 23%; D‑VTd: 22%, VTd: 20%.).

Pneumonia was the most commonly reported severe (Grade 3 or 4) infection across studies. In active controlled studies, Ddiscontinuations from treatment due to infections were reportedoccurred in 1-4% to 5% of patients. Fatal infections were generally balanced between the intravenous daratumumab containing regimens and active control arms (<2%) in the controlled studies and were primarily due to pneumonia and sepsis.

In patients receiving intravenous daratumumab combination therapy, fatal infections (Grade 5) were reported as follows:

Relapsed/refractory patient studies: DVd: 1%, Vd: 2%; DRd: 2%, Rd: 1%; DPd: 2%

Newly diagnosed patient studies: D-VMP: 1%, VMP: 1%; DRd: 2%, Rd: 2%; DVTd: 0%, VTd: 0%.

Key: D=daratumumab; Vd=bortezomib-dexamethasone; Rd=lenalidomide-dexamethasone; Pd=pomalidomide-dexamethasone; VMP=bortezomib-melphalan-prednisone; VTd=bortezomib-thalidomide-dexamethasone.

 

 

………………….

 

Elderly patients

Of the 3207 patients who received daratumumab (n=490 subcutaneous; n=2717 intravenous) at the recommended dose, 38% were 65 to 75 years of age, and 17% were 75 years of age or older. No overall differences in effectiveness were observed based on age. The incidence of serious adverse reactions was higher in older than in younger patients. Among patients with relapsed and refractory multiple myeloma (n=1827), the most common serious adverse reactions that occurred more frequently in elderly (≥65 years of age) were pneumonia and sepsis. Among patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (n=777), the most common serious adverse reaction that occurred more frequently in elderly (≥75 years of age) was pneumonia.

 

Updated on 23 July 2020

File name

Darzalex IV- SmPC C13-Clean-11 June 2020.pdf

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

 

 

Immunogenicity

In patients treated with intravenous daratumumab in clinical trials, less than 1% of patients developed treatment-emergent anti-daratumumab antibodies.Patients treated with daratumumab monotherapy (n=199) and combination therapy (n=1051) were evaluated for anti‑therapeutic antibody responses to daratumumab at multiple time points during treatment and up to 8 weeks following the end of treatment. Following the start of daratumumab treatment, none of the monotherapy patients and 2 of the 1051 combination therapy patients tested positive for anti‑daratumumab antibodies; 1 of the combination therapy patients developed transient neutralising antibodies against daratumumab.

However, the employed assay has limitations in detecting anti‑daratumumab antibodies in the presence of high concentrations of daratumumab. Therefore, the incidence of antibody development might not have been reliably determined

EDM Updated on 10 July 2020

File name

Patient Card - Darzalex.pdf

Reasons for updating

  • Add New Doc

EDM Updated on 10 July 2020

File name

Darzalex RMP Blood Lab Card June 2020 Update.pdf

Reasons for updating

  • Add New Doc

EDM Updated on 10 July 2020

File name

Darzalex RMP HCP Card June 2020.pdf

Reasons for updating

  • Add New Doc

Updated on 22 April 2020

File name

C12 SmPC_Darzalex IV-26 March 2020-CLEAN-approved.pdf

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

5.1     Pharmacodynamic properties

 ………….

 

A total of 706 patients were randomised: 350 to the D-VMP arm and 356 to the VMP arm. The baseline demographic and disease characteristics were similar between the two treatment groups. The median age was 71 (range: 40-93) years, with 30% of the patients ≥75 years of age. The majority were white (85%), female (54%), 25% had an ECOG performance score of 0, 50% had an ECOG performance score of 1 and 25% had an ECOG performance score of 2. Patients had IgG/IgA/Light chain myeloma in 64%/22%/10% of instances, 19% had ISS Stage I, 42% had ISS Stage II, 38% had ISS Stage III disease and 84% had standard risk cytogenetics. Efficacy was evaluated by PFS based on IMWG criteria and overall survival (OS).

 

With a median followup of 16.5 months, Tthe primary analysis of PFS in Study MMY3007 showed an improvement in the D-VMP arm as compared to the VMP arm; the median PFS had not been reached in the D-VMP arm and was 18.1 months in the VMP arm (HR=0.5; 95% CI: 0.38, 0.65; p<0.0001)., representing 50% reduction in the risk of disease progression or death in patients treated with D-VMP. Results of an updated PFS analysis approximately 4 months after the original clinical cutoff, continued to show an improvement in PFS for patients in the D-VMP arm compared with the VMP arm. Median PFS was not reached in the D-VMP arm and was 19.3 months in the VMP arm (HR=0.46; 95% CI: 0.36, 0.60; p<0.0001). Results of an updated PFS analysis after a median followup of 40 months continued to show an improvement in PFS for patients in the DVMP arm compared with the VMP arm. Median PFS was 36.4 months in the DVMP arm and 19.3 months in the VMP arm (HR=0.42; 95% CI: 0.34, 0.51; p<0.0001), representing a 58% reduction in the risk of disease progression or death in patients treated with DVMP.

 

Figure 2:        Kaplan-Meier Curve of Primary Analysis of PFS in Study MMY3007

 

 

After a median followup of 40 months, DVMP has shown an overall survival (OS) advantage over the VMP arm (HR=0.60; 95% CI: 0.46, 0.80; p=0.0003), representing a 40% reduction in the risk of death in patients treated in the DVMP arm. Median OS was not reached for either arm.

 

 

……………………

 

With a median followup of 13.5 months, the primary analysis of PFS in Sstudy MMY3003 demonstrated an improvement in PFS in the DRd arm as compared to the Rd arm; the median PFS had not been reached in the DRd arm and was 18.4 months in the Rd arm (HR=0.37; 95% CI: 0.27, 0.52; p<0.0001)., representing 63% reduction in the risk of disease progression or death in patients treated with DRd Results of an updated PFS analysis after a median followup of 55 months continued to show an improvement in PFS for patients in the DRd arm compared with the Rd arm. Median PFS was 45.0 months in the DRd arm and 17.5 months in the Rd arm (HR=0.44; 95% CI: 0.35, 0.54; p<0.0001), representing a 56% reduction in the risk of disease progression or death in patients treated with DRd (see Figure 34).

 

Figure 34:      Kaplan-Meier Curve of PFS in Study MMY3003

 

 

……..

Table 11:         Additional efficacy results from Study MMY3003

Response evaluable patient number

DRd (n=281)

Rd (n=276)

Overall response (sCR+CR+VGPR+PR) n(%)

261 (92.9)

211 (76.4)

p-valuea

< 0.0001

 

Stringent complete response (sCR)

51 (18.1)

20 (7.2)

Complete response (CR)

70 (24.9)

33 (12.0)

Very good partial response (VGPR)

92 (32.7)

69 (25.0)

Partial response (PR)

48 (17.1)

89 (32.2)

Median Time to Response [months (95% CI)]

1.0 (1.0, 1.1)

1.3 (1.1, 1.9)

Median Duration of Response [months (95% CI)]

NE (NE, NE)

17.4 (17.4, NE)

MRD negative rate (95% CI) b (%)

29.021.0 (23.816.4, 34.726.2)

7.82.8 (4.91.2, 11.55.5)

Odds ratio with 95% CIc

4.859.31 (2.934.31, 8.0320.09)

 

P-valued

< 0.000001

 

DRd=daratumumab-lenalidomide-dexamethasone; Rd=lenalidomide-dexamethasone; MRD=minimal residual disease; CI=confidence interval; NE=not estimable.

a     p-value from Cochran Mantel-Haenszel Chi-Squared test.

b       Based on Intent-to-treat population and threshold of 10-4

c    A Chi-Squared MantelHaenszel estimate of the common odds ratio is used. An odds ratio >1 indicates an advantage for DRd.

d     p-value is from a likelihood-ratio Chi-SquaredFisher’s exact test.

………….

 

 

With a median followup of 7.4 months, the primary analysis of PFS in Sstudy MMY3004 demonstrated an improvement in PFS in the DVd arm as compared to the Vd arm; the median PFS had not been reached in the DVd arm and was 7.2 months in the Vd arm (HR [95% CI]: 0.39 [0.28, 0.53]; p-value<0.0001), representing a 61% reduction in the risk of disease progression or death for patients treated with DVd versus Vd. Results of an updated PFS analysis after a median followup of 50 months continued to show an improvement in PFS for patients in the DVd arm compared with the Vd arm. Median PFS was 16.7 months in the DVd arm and 7.1 months in the Vd arm (HR [95% CI]: 0.31 [0.24, 0.39]; p-value<0.0001), representing a 69% reduction in the risk of disease progression or death in patients treated with DVd versus Vd (see Figure 45).

 

Table 12:    Additional efficacy results from Study MMY3004

Response evaluable patient number

DVd (n=240)

Vd (n=234)

Overall response (sCR+CR+VGPR+PR) n(%)

199 (82.9)

148 (63.2)

P-valuea

< 0.0001

 

Stringent complete response (sCR)

11 (4.6)

5 (2.1)

Complete response (CR)

35 (14.6)

16 (6.8)

Very good partial response (VGPR)

96 (40.0)

47 (20.1)

Partial response (PR)

57 (23.8)

80 (34.2)

Median Time to Response [months (range)]

0.9 (0.8, 1.4)

1.6 (1.5, 2.1)

Median Duration of Response [months (95% CI)]

NE (11.5, NE)

7.9 (6.7, 11.3)

MRD negative rate (95% CI)b

13.58.8% (9.65.6%, 18.413.0%)

2.81.2% (1.10.3%, 5.83.5%)

Odds ratio with 95% CIc

5.379.04 (2.332.53, 12.3732.21)

 

P-valued

0.0000060.0001

 

DVd=daratumumab- bortezomib-dexamethasone; Vd=bortezomib-dexamethasone; MRD=minimal residual disease; CI=confidence interval; NE=not estimable.

a     p-value from Cochran Mantel-Haenszel Chi-Squared test.

b     Based on Intent-to-treat population and threshold of 10-4

c     A Chi-Squared Mantel-Haenszel estimate of the common odds ratio is used. An odds ratio > 1 indicates an advantage for DVd.

d     p-value is from a likelihood-ratio chi-squaredFisher’s exact test.

 

Updated on 22 January 2020

File name

C11 SmPC_Darzalex-20 Jan 2020-030-Clean.pdf

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.1       Therapeutic indications

 

DARZALEX is indicated:

  • in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
  • in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
  • in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
  • as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.
     
     
    4.2       Posology and method of administration
    Dosing schedule in combination with bortezomib, thalidomide and dexamethasone (4-week cycle regimens) for treatment of newly diagnosed patients eligible for autologous stem cell transplant (ASCT):

The recommended dose is DARZALEX 16 mg/kg body weight administered as an intravenous infusion according to the following dosing schedule in Table 3.

 

Table 3:            DARZALEX dosing schedule in combination with bortezomib, thalidomide and dexamethasone ([VTd]; 4-week cycle dosing regimen)

Treatment phase

Weeks

Schedule

Induction

Weeks 1 to 8

weekly (total of 8 doses)

Weeks 9 to 16a

every two weeks (total of 4 doses)

Stop for high dose chemotherapy and ASCT

Consolidation

Weeks 1 to 8b

every two weeks (total of 4 doses)

a        First dose of the every-2-week dosing schedule is given at Week 9

b        First dose of the every-2-week dosing schedule is given at Week 1 upon re-initiation of treatment following ASCT

 

For dose and schedule of medicinal products administered with DARZALEX, see section 5.1 and the corresponding Summary of Product Characteristics.

 

 

4.8       Undesirable effects

 

Summary of the safety profile

The most frequent adverse reactions (≥ 20%) were infusion reactions, fatigue, nausea, diarrhoea, constipation, pyrexia, dyspnoea, cough, back pain, neutropenia, thrombocytopenia, anaemia, oedema peripheral, asthenia, peripheral sensory neuropathy and upper respiratory tract infection. Serious adverse reactions were pneumonia, bronchitis, upper respiratory tract infection, pulmonary oedema, influenza, pyrexia, dehydration, diarrhoea and atrial fibrillation.

 

Tabulated list of adverse reactions

Table 5 6 summarises the adverse drug reactions that occurred in patients receiving DARZALEX. The data reflects exposure to DARZALEX (16 mg/kg) in 1530 2066 patients with multiple myeloma including 1374 1910 patients who received DARZALEX in combination with background regimens and 156 patients who received DARZALEX as monotherapy. Post‑marketing adverse reactions are also included.

 

In Study MMY3006, the number of CD34+ cell yield was numerically lower in the D-VTd arm compared with the VTd arm (Median: D-VTd: 6.3 x 106/kg; VTd 8.9 x 106/kg) and among those who completed mobilization, more patients in the D-VTd group received plerixafor compared to those in the VTd arm (D-VTd: 21.7%; VTd: 7.9%). The rates of engraftment and haematopoietic reconstitution was similar among the transplanted subjects in the D-VTd and VTd arms (D-VTd: 99.8%; VTd: 99.6%; as measured by the recovery of neutrophils > 0.5 x 109/L, leukocytes > 1.0 x 109/L, and platelets > 50 x 109/L without transfusion).

Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000) and very rare (< 1/10,000). Within each frequency grouping, where relevant, adverse reactions are presented in order of decreasing seriousness.

 

 

Table 56:    Adverse reactions in multiple myeloma patients treated with DARZALEX 16 mg/kg

System Organ Class

Adverse reaction

Frequency

Incidence (%)

Any Grade

Grade 3‑4

Infections and infestations

Pneumoniaa

Very Common

1816

1210

Bronchitisa

1617

2

Upper respiratory tract infectiona

4641

3

Urinary tract infection

Common

98

21

Influenza

5

1*

Hepatitis B Virus reactivationb

Uncommon

-

-

Blood and lymphatic system disorders

Neutropeniaa

Very Common

4845

4139

Thrombocytopeniaa

3531

2219

Anaemiaa

3227

1512

Lymphopeniaa

1214

1011

Leukopeniaa

1412

86

Immune system disorders

Anaphylactic reactionb

Rare

-

-

Metabolism and nutrition disorders

Decreased appetite

Very Common

1412

1*

Hyperglycemia

Common

97

43

Hypocalcemia

76

21

Dehydration

3

1*

Nervous system disorders

Peripheral sensory neuropathy

Very Common

 

2332

32

Paraesthesia

11

< 1

Headache

1312

< 1*

Paraesthesia

Common

7

< 1

Cardiac disorders

Atrial fibrillation

Common

4

21

Vascular disorders

Hypertensiona

Very Common

1110

5

Respiratory, thoracic and mediastinal disorders

Cougha

Very Common

2825

< 1*

Dyspnoeaa

2221

3

Pulmonary oedemaa

Common

1

<1

Gastrointestinal disorders

Diarrhoea

Very Common

3732

4

Constipation

2733

1

Nausea

2426

1*2*

Vomiting

16

1*

Pancreatitisa

Common

1

1

Musculoskeletal and connective tissue disorders

Back pain

Very Common

2119

2

Muscle spasms

1714

< 1*

General disorders and administration site conditions

Fatigue

Very Common

3126

54

Oedema peripherala

2526

1

Pyrexia

2123

1*2

Asthenia

1721

2

Chills

Common

9

< 1*

Injury, poisoning and procedural complications

Infusion‑related reactionc

Very Common

4240

54

*   No Grade 4

a    Indicates grouping of terms

b    Post‑marketing adverse reaction

c    Infusion-related reaction includes terms determined by investigators to be related to infusion, see below

 

Infusion‑related reactions

In clinical trials…….. vomiting and nausea (see section 4.4).

 

When DARZALEX dosing was interrupted in the setting of ASCT (Study MMY3006) for a median of 3.75 (range: 2.4; 6.9) months, upon re-initiation of DARZALEX the incidence of IRRs was 11% at first infusion following ASCT. Infusion rate/dilution volume used upon re-initiation was that used for the last DARZALEX infusion prior to interruption due to ASCT. IRRs occurring at re-initiation of DARZALEX following ASCT were consistent in terms of symptoms and severity (Grade 3/4: <1%) with those reported in previous studies at Week 2 or subsequent infusions.

….

 

Infections

In patients receiving DARZALEX combination therapy, Grade 3 or 4 infections were reported as follows:

Relapsed/refractory patient studies: DVd: 21%, Vd: 19%; DRd: 27%, Rd: 23%; DPd: 28%

Newly diagnosed patient studies: D‑VMP: 23%, VMP: 15%; DRd: 32%, Rd: 23%; D-VTd: 22%, VTd: 20%.

Pneumonia was the most commonly reported severe (Grade 3 or 4) infection across studies. In the active controlled studies, discontinuations from treatment due to infections (1-4%) and fatal infections were generally infrequent and balanced between the DARZALEX containing regimens and active control arms. Fatal infections were primarily due to pneumonia and sepsis.

Key: D=daratumumab; Vd=bortezomib-dexamethasone; Rd=lenalidomide-dexamethasone; Pd=pomalidomide-dexamethasone; VMP=bortezomib-melphalan-prednisone; VTd=bortezomib-thalidomide-dexamethasone.

 

5.       PHARMACOLOGICAL PROPERTIES

 

5.1     Pharmacodynamic properties

 

Combination treatment with bortezomib, thalidomide and dexamethasone (VTd) in patients eligible for autologous stem cell transplant (ASCT):

Study MMY3006 is a 2 Part, open-label, randomized, active-controlled Phase 3 study. Part 1 compared induction and consolidation treatment with DARZALEX 16 mg/kg in combination with bortezomib, thalidomide and dexamethasone (D-VTd) to treatment with bortezomib, thalidomide and dexamethasone (VTd) in patients with newly diagnosed multiple myeloma eligible for ASCT. The consolidation phase of treatment began a minimum of 30 days post-ASCT, when the patient had recovered sufficiently, and engraftment was complete. In Part 2, subjects with at least a partial response (PR) by Day 100 post-transplant were re-randomized in a 1:1 ratio to daratumumab maintenance or observation only. Only results from Part 1 are described henceforth.

 

Bortezomib was administered by SC injection or IV injection at a dose of 1.3 mg/m2 body surface area twice weekly for two weeks (Days 1, 4, 8, and 11) of repeated 28 day (4-week) induction treatment cycles (Cycles 1-4) and two consolidation cycles (Cycles 5 and 6) following ASCT after Cycle 4. Thalidomide was administered orally at 100 mg daily during the six bortezomib cycles. Dexamethasone (oral or intravenous) was administered at 40 mg on Days 1, 2, 8, 9, 15, 16, 22 and 23 of Cycles 1 and 2, and at 40 mg on Days 1-2 and 20 mg on subsequent dosing days (Days 8, 9, 15, 16) of Cycles 3-4. Dexamethasone 20 mg was administered on Days 1, 2, 8, 9, 15, 16 in Cycles 5 and 6. On the days of DARZALEX infusion, the dexamethasone dose was administered intravenously as a pre-infusion medication. Dose adjustments for bortezomib, thalidomide and dexamethasone were applied according to manufacturer’s prescribing information.

 

A total of 1085 patients were randomized: 543 to the D-VTd arm and 542 to the VTd arm. The baseline demographic and disease characteristics were similar between the two treatment groups. The median age was 58 (range: 22 to 65) years. All patients were ≤ 65 years: 43% were in the age group ≥ 60-65 years, 41% were in the age group ≥ 50-60 years and 16% below age of 50 years. The majority were male (59%), 48% had an ECOG performance score of 0, 42% had an ECOG performance score of 1 and 10% had an ECOG performance score of 2. Forty percent had International Staging System (ISS) Stage I, 45% had ISS Stage II and 15% had ISS Stage III disease.

 

Efficacy was evaluated by the stringent Complete Response (sCR) rate at Day 100 post-transplant and Progression free survival (PFS).

 

Table 9:           Efficacy results from Study MMY3006a

 

D-VTd (n=543)

VTd (n=542)

P valueb

Response assessment Day 100 post-transplant

 

 

 

Stringent Complete Response (sCR)

157 (28.9%)

110 (20.3%)

0.0010

CR or better (sCR+CR)

211 (38.9%)

141 (26.0%)

<0.0001

Very Good Partial Response or better (sCR+CR+VGPR)

453 (83.4%)

423 (78.0%)

 

MRD negativityc, d n(%)

346 (63.7%)

236 (43.5%)

<0.0001

95% CI (%)

(59.5%, 67.8%)

(39.3%, 47.8%)

 

Odds ratio with 95% CIe

2.27 (1.78, 2.90)

 

MRD negativity in combination with CR or betterc n(%)

183 (33.7%)

108 (19.9%)

<0.0001

95% CI (%)

(29.7%, 37.9%)

(16.6%, 23.5%)

 

Odds ratio with 95% CIe

2.06 (1.56, 2.72)

 

D-VTd=daratumumab-bortezomib-thalidomide-dexamethasone; VTd=bortezomib-thalidomide-dexamethasone; MRD=minimal residual disease; CI=confidence interval

a       Based on intent-to-treat population

b       p-value from Cochran Mantel-Haenszel Chi-Squared test.

c       Based on threshold of 10-5

d       Regardless of response per IMWG

e          Mantel-Haenszel estimate of the common odds ratio for stratified tables is used.

 

Results of a PFS analysis by censoring patients who were randomized to daratumumab maintenance in the second randomization, at the date of the second randomization showed HR=0.50; 95% CI: 0.34, 0.75; p=0.0005.

 

 

 

 

4.1       Therapeutic indications

 

DARZALEX is indicated:

  • in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
  • in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
  • in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
  • as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.
     
     
    4.2       Posology and method of administration
    Dosing schedule in combination with bortezomib, thalidomide and dexamethasone (4-week cycle regimens) for treatment of newly diagnosed patients eligible for autologous stem cell transplant (ASCT):

The recommended dose is DARZALEX 16 mg/kg body weight administered as an intravenous infusion according to the following dosing schedule in Table 3.

 

Table 3:            DARZALEX dosing schedule in combination with bortezomib, thalidomide and dexamethasone ([VTd]; 4-week cycle dosing regimen)

Treatment phase

Weeks

Schedule

Induction

Weeks 1 to 8

weekly (total of 8 doses)

Weeks 9 to 16a

every two weeks (total of 4 doses)

Stop for high dose chemotherapy and ASCT

Consolidation

Weeks 1 to 8b

every two weeks (total of 4 doses)

a        First dose of the every-2-week dosing schedule is given at Week 9

b        First dose of the every-2-week dosing schedule is given at Week 1 upon re-initiation of treatment following ASCT

 

For dose and schedule of medicinal products administered with DARZALEX, see section 5.1 and the corresponding Summary of Product Characteristics.

 

 

4.8       Undesirable effects

 

Summary of the safety profile

The most frequent adverse reactions (≥ 20%) were infusion reactions, fatigue, nausea, diarrhoea, constipation, pyrexia, dyspnoea, cough, back pain, neutropenia, thrombocytopenia, anaemia, oedema peripheral, asthenia, peripheral sensory neuropathy and upper respiratory tract infection. Serious adverse reactions were pneumonia, bronchitis, upper respiratory tract infection, pulmonary oedema, influenza, pyrexia, dehydration, diarrhoea and atrial fibrillation.

 

Tabulated list of adverse reactions

Table 5 6 summarises the adverse drug reactions that occurred in patients receiving DARZALEX. The data reflects exposure to DARZALEX (16 mg/kg) in 1530 2066 patients with multiple myeloma including 1374 1910 patients who received DARZALEX in combination with background regimens and 156 patients who received DARZALEX as monotherapy. Post‑marketing adverse reactions are also included.

 

In Study MMY3006, the number of CD34+ cell yield was numerically lower in the D-VTd arm compared with the VTd arm (Median: D-VTd: 6.3 x 106/kg; VTd 8.9 x 106/kg) and among those who completed mobilization, more patients in the D-VTd group received plerixafor compared to those in the VTd arm (D-VTd: 21.7%; VTd: 7.9%). The rates of engraftment and haematopoietic reconstitution was similar among the transplanted subjects in the D-VTd and VTd arms (D-VTd: 99.8%; VTd: 99.6%; as measured by the recovery of neutrophils > 0.5 x 109/L, leukocytes > 1.0 x 109/L, and platelets > 50 x 109/L without transfusion).

Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000) and very rare (< 1/10,000). Within each frequency grouping, where relevant, adverse reactions are presented in order of decreasing seriousness.

 

 

Table 56:    Adverse reactions in multiple myeloma patients treated with DARZALEX 16 mg/kg

System Organ Class

Adverse reaction

Frequency

Incidence (%)

Any Grade

Grade 3‑4

Infections and infestations

Pneumoniaa

Very Common

1816

1210

Bronchitisa

1617

2

Upper respiratory tract infectiona

4641

3

Urinary tract infection

Common

98

21

Influenza

5

1*

Hepatitis B Virus reactivationb

Uncommon

-

-

Blood and lymphatic system disorders

Neutropeniaa

Very Common

4845

4139

Thrombocytopeniaa

3531

2219

Anaemiaa

3227

1512

Lymphopeniaa

1214

1011

Leukopeniaa

1412

86

Immune system disorders

Anaphylactic reactionb

Rare

-

-

Metabolism and nutrition disorders

Decreased appetite

Very Common

1412

1*

Hyperglycemia

Common

97

43

Hypocalcemia

76

21

Dehydration

3

1*

Nervous system disorders

Peripheral sensory neuropathy

Very Common

 

2332

32

Paraesthesia

11

< 1

Headache

1312

< 1*

Paraesthesia

Common

7

< 1

Cardiac disorders

Atrial fibrillation

Common

4

21

Vascular disorders

Hypertensiona

Very Common

1110

5

Respiratory, thoracic and mediastinal disorders

Cougha

Very Common

2825

< 1*

Dyspnoeaa

2221

3

Pulmonary oedemaa

Common

1

<1

Gastrointestinal disorders

Diarrhoea

Very Common

3732

4

Constipation

2733

1

Nausea

2426

1*2*

Vomiting

16

1*

Pancreatitisa

Common

1

1

Musculoskeletal and connective tissue disorders

Back pain

Very Common

2119

2

Muscle spasms

1714

< 1*

General disorders and administration site conditions

Fatigue

Very Common

3126

54

Oedema peripherala

2526

1

Pyrexia

2123

1*2

Asthenia

1721

2

Chills

Common

9

< 1*

Injury, poisoning and procedural complications

Infusion‑related reactionc

Very Common

4240

54

*   No Grade 4

a    Indicates grouping of terms

b    Post‑marketing adverse reaction

c    Infusion-related reaction includes terms determined by investigators to be related to infusion, see below

 

Infusion‑related reactions

In clinical trials…….. vomiting and nausea (see section 4.4).

 

When DARZALEX dosing was interrupted in the setting of ASCT (Study MMY3006) for a median of 3.75 (range: 2.4; 6.9) months, upon re-initiation of DARZALEX the incidence of IRRs was 11% at first infusion following ASCT. Infusion rate/dilution volume used upon re-initiation was that used for the last DARZALEX infusion prior to interruption due to ASCT. IRRs occurring at re-initiation of DARZALEX following ASCT were consistent in terms of symptoms and severity (Grade 3/4: <1%) with those reported in previous studies at Week 2 or subsequent infusions.

….

 

Infections

In patients receiving DARZALEX combination therapy, Grade 3 or 4 infections were reported as follows:

Relapsed/refractory patient studies: DVd: 21%, Vd: 19%; DRd: 27%, Rd: 23%; DPd: 28%

Newly diagnosed patient studies: D‑VMP: 23%, VMP: 15%; DRd: 32%, Rd: 23%; D-VTd: 22%, VTd: 20%.

Pneumonia was the most commonly reported severe (Grade 3 or 4) infection across studies. In the active controlled studies, discontinuations from treatment due to infections (1-4%) and fatal infections were generally infrequent and balanced between the DARZALEX containing regimens and active control arms. Fatal infections were primarily due to pneumonia and sepsis.

Key: D=daratumumab; Vd=bortezomib-dexamethasone; Rd=lenalidomide-dexamethasone; Pd=pomalidomide-dexamethasone; VMP=bortezomib-melphalan-prednisone; VTd=bortezomib-thalidomide-dexamethasone.

 

5.       PHARMACOLOGICAL PROPERTIES

 

5.1     Pharmacodynamic properties

 

Combination treatment with bortezomib, thalidomide and dexamethasone (VTd) in patients eligible for autologous stem cell transplant (ASCT):

Study MMY3006 is a 2 Part, open-label, randomized, active-controlled Phase 3 study. Part 1 compared induction and consolidation treatment with DARZALEX 16 mg/kg in combination with bortezomib, thalidomide and dexamethasone (D-VTd) to treatment with bortezomib, thalidomide and dexamethasone (VTd) in patients with newly diagnosed multiple myeloma eligible for ASCT. The consolidation phase of treatment began a minimum of 30 days post-ASCT, when the patient had recovered sufficiently, and engraftment was complete. In Part 2, subjects with at least a partial response (PR) by Day 100 post-transplant were re-randomized in a 1:1 ratio to daratumumab maintenance or observation only. Only results from Part 1 are described henceforth.

 

Bortezomib was administered by SC injection or IV injection at a dose of 1.3 mg/m2 body surface area twice weekly for two weeks (Days 1, 4, 8, and 11) of repeated 28 day (4-week) induction treatment cycles (Cycles 1-4) and two consolidation cycles (Cycles 5 and 6) following ASCT after Cycle 4. Thalidomide was administered orally at 100 mg daily during the six bortezomib cycles. Dexamethasone (oral or intravenous) was administered at 40 mg on Days 1, 2, 8, 9, 15, 16, 22 and 23 of Cycles 1 and 2, and at 40 mg on Days 1-2 and 20 mg on subsequent dosing days (Days 8, 9, 15, 16) of Cycles 3-4. Dexamethasone 20 mg was administered on Days 1, 2, 8, 9, 15, 16 in Cycles 5 and 6. On the days of DARZALEX infusion, the dexamethasone dose was administered intravenously as a pre-infusion medication. Dose adjustments for bortezomib, thalidomide and dexamethasone were applied according to manufacturer’s prescribing information.

 

A total of 1085 patients were randomized: 543 to the D-VTd arm and 542 to the VTd arm. The baseline demographic and disease characteristics were similar between the two treatment groups. The median age was 58 (range: 22 to 65) years. All patients were ≤ 65 years: 43% were in the age group ≥ 60-65 years, 41% were in the age group ≥ 50-60 years and 16% below age of 50 years. The majority were male (59%), 48% had an ECOG performance score of 0, 42% had an ECOG performance score of 1 and 10% had an ECOG performance score of 2. Forty percent had International Staging System (ISS) Stage I, 45% had ISS Stage II and 15% had ISS Stage III disease.

 

Efficacy was evaluated by the stringent Complete Response (sCR) rate at Day 100 post-transplant and Progression free survival (PFS).

 

Table 9:           Efficacy results from Study MMY3006a

 

D-VTd (n=543)

VTd (n=542)

P valueb

Response assessment Day 100 post-transplant

 

 

 

Stringent Complete Response (sCR)

157 (28.9%)

110 (20.3%)

0.0010

CR or better (sCR+CR)

211 (38.9%)

141 (26.0%)

<0.0001

Very Good Partial Response or better (sCR+CR+VGPR)

453 (83.4%)

423 (78.0%)

 

MRD negativityc, d n(%)

346 (63.7%)

236 (43.5%)

<0.0001

95% CI (%)

(59.5%, 67.8%)

(39.3%, 47.8%)

 

Odds ratio with 95% CIe

2.27 (1.78, 2.90)

 

MRD negativity in combination with CR or betterc n(%)

183 (33.7%)

108 (19.9%)

<0.0001

95% CI (%)

(29.7%, 37.9%)

(16.6%, 23.5%)

 

Odds ratio with 95% CIe

2.06 (1.56, 2.72)

 

D-VTd=daratumumab-bortezomib-thalidomide-dexamethasone; VTd=bortezomib-thalidomide-dexamethasone; MRD=minimal residual disease; CI=confidence interval

a       Based on intent-to-treat population

b       p-value from Cochran Mantel-Haenszel Chi-Squared test.

c       Based on threshold of 10-5

d       Regardless of response per IMWG

e          Mantel-Haenszel estimate of the common odds ratio for stratified tables is used.

 

Results of a PFS analysis by censoring patients who were randomized to daratumumab maintenance in the second randomization, at the date of the second randomization showed HR=0.50; 95% CI: 0.34, 0.75; p=0.0005.

 

 

 

 

Updated on 22 January 2020

File name

IRE C10 PIL-Darzalex- 20 Jan 2020-030-Clean.pdf

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 20 November 2019

File name

IRE C09 PIL-Darzalex- 19 Nov2019-Clean.pdf

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 20 November 2019

File name

C10 SmPC-Darzalex- 19 Nov2019-029-Clean.pdf

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.1     Therapeutic indications

 

DARZALEX is indicated:

  • in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
  • as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.
  • in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
  • as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.

 

 

4.2     Posology and method of administration

 

DARZALEX should be administered by a healthcare professional, in an environment where resuscitation facilities are available.

 

Pre‑ and post‑infusion medications should be administered to reduce the risk of infusion‑related reactions (IRRs) with daratumumab. See below “Recommended concomitant medications”, “Management of infusion‑related reactions” and section 4.4.

 

 

Posology

Dosing schedule in combination with lenalidomide (4‑week cycle regimen) and for monotherapy:

The recommended dose is DARZALEX 16 mg/kg body weight administered as an intravenous infusion according to the following dosing schedule in Table 1.

 

Table 1:      DARZALEX dosing schedule in combination with lenalidomide (4-week cycle dosing regimen) and monotherapy

Weeks

Schedule

Weeks 1 to 8

weekly (total of 8 doses)

Weeks 9 to 24a

every two weeks (total of 8 doses)

Week 25 onwards until disease progressionb

every four weeks

a    First dose of the every-2-week dosing schedule is given at Week 9

b    First dose of the every-4-week dosing schedule is given at Week 25

 

For dose and schedule of medicinal products administered with DARZALEX, see section 5.1 and the corresponding Summary of Product Characteristics.

 

Newly diagnosed multiple myeloma

Dosing schedule in combination with bortezomib, melphalan and prednisone (6-week cycle regimens) for patients ineligible for autologous stem cell transplant:

 

The recommended dose is DARZALEX 16 mg/kg body weight administered as an intravenous infusion according to the following dosing schedule in Table 12.

 

Table 12:        DARZALEX dosing schedule in combination with bortezomib, melphalan and prednisone ([VMP]; 6-week cycle dosing regimen)

Weeks

Schedule

Weeks 1 to 6

weekly (total of 6 doses)

Weeks 7 to 54a

every three weeks (total of 16 doses)

Week 55 onwards until disease progressionb

every four weeks

a     First dose of the every-3-week dosing schedule is given at Week 7

b        First dose of the every-4-week dosing schedule is given at Week 55

 

Bortezomib is given twice weekly at Weeks 1, 2, 4 and 5 for the first 6-week cycle, followed by once weekly at Weeks 1, 2, 4 and 5 for eight more 6-week cycles. For information on the VMP dose and dosing schedule when administered with DARZALEX, see section 5.1.

 

Relapsed/Refractory multiple myeloma

Dosing schedule for monotherapy and in combination with lenalidomide (4‑week cycle regimen):

The recommended dose is DARZALEX 16 mg/kg body weight administered as an intravenous infusion according to the following dosing schedule in Table 2.

 

Table 2:      DARZALEX dosing schedule for monotherapy and in combination with lenalidomide (4-week cycle dosing regimen)

Weeks

Schedule

Weeks 1 to 8

weekly (total of 8 doses)

Weeks 9 to 24a

every two weeks (total of 8 doses)

Week 25 onwards until disease progressionb

every four weeks

a    First dose of the every-2-week dosing schedule is given at Week 9

b    First dose of the every-4-week dosing schedule is given at Week 25

 

For dose and schedule of medicinal products administered with DARZALEX, see section 5.1 and the corresponding Summary of Product Characteristics.

 

 

4.5     Interaction with other medicinal products and other forms of interaction

 

……

 

Clinical pharmacokinetic assessments of daratumumab in combination with lenalidomide, pomalidomide, thalidomide, and bortezomib and dexamethasone indicated no clinically-relevant drug-drug interaction between DARZALEX and these combination therapiessmall molecule medicinal products.

 

 

4.8     Undesirable effects

 

Summary of the safety profile

The most frequent adverse reactions (≥ 20%) were infusion reactions, fatigue, nausea, diarrhoea, muscle spasmsconstipation, pyrexia, dyspnoea, cough, back pain, neutropenia, thrombocytopenia, anaemia, oedema peripheral, peripheral sensory neuropathy and upper respiratory tract infection. Serious adverse reactions were pneumonia, bronchitis, upper respiratory tract infection, pulmonary oedema, influenza, pyrexia, dehydration, diarrhoea and atrial fibrillation.

 

Tabulated list of adverse reactions

Table 5 summarises the adverse drug reactions that occurred in patients receiving DARZALEX. The data reflects exposure to DARZALEX (16 mg/kg) in 1530 patients with multiple myeloma including 1374 patients who received DARZALEX in combination with background regimens and 156 patients who received DARZALEX as monotherapy 1166 patients with multiple myeloma including 872 patients from three Phase III active-controlled trials who received DARZALEX in combination with either lenalidomide and dexamethasone (DRd; n=283; Study MMY3003), bortezomib and dexamethasone (DVd; n=243; Study MMY3004), or bortezomib, melphalan and prednisone (D‑VMP, n=346; Study MMY3007), and five open-label, clinical trials in which patients received DARZALEX either in combination with pomalidomide and dexamethasone (DPd; n=103), in combination with lenalidomide and dexamethasone (n=35) or as monotherapy (n=156). Post‑marketing adverse reactions are also included.

 

Table 5:      Adverse reactions in multiple myeloma patients treated with DARZALEX 16 mg/kg

System Organ Class

Adverse reaction

Frequency

Incidence (%)

Any Grade

Grade 3‑4

Infections and infestations

Pneumoniaa

Very Common

1618

1112

Bronchitisa

16

2

Upper respiratory tract infectiona

5046

53

Urinary tract infection

Common

9

2

Influenza

5

1*

Influenza

Common

4

1*

Hepatitis B Virus reactivationb

Uncommon

-

-

Blood and lymphatic system disorders

Neutropeniaa

Very Common

4648

3841

Thrombocytopeniaa

4035

2722

Anaemiaa

3032

1615

Lymphopeniaa

1012

810

Leukopeniaa

14

8

Immune system disorders

Anaphylactic reactionb

Rare

-

-

Metabolism and nutrition disorders

Decreased appetite

Very Common

14

1*

Hyperglycemia

Common

9

4

Hypocalcemia

7

2

Dehydration

3

1*

Nervous system disorders

Peripheral sensory neuropathy

Very Common

 

2223

2

Headache

1113

< 1*

Paraesthesia

Common

7

< 1

Cardiac disorders

Atrial fibrillation

Common

4

12

Vascular disorders

Hypertensiona

Very Common

1011

5

Respiratory, thoracic and mediastinal disorders

Cougha

Very Common

2728

< 1*

Dyspnoeaa

1922

3

Pulmonary oedemaa

Common

1

1

Gastrointestinal disorders

Diarrhoea

Very Common

3137

34

Constipation

27

1

Nausea

2224

1*

Vomiting

1516

1*

Musculoskeletal and connective tissue disorders

Back pain

Very Common

21

2

Muscle spasms

1317

< 1*

General disorders and administration site conditions

Fatigue

Very Common

31

5

Oedema peripherala

25

1

Pyrexia

21

1*

Asthenia

17

2

Chills

Common

9

< 1*

General disorders and administration site conditions

Fatigue

Very Common

28

5

Pyrexia

21

1*

Oedema peripherala

19

1

Injury, poisoning and procedural complications

Infusion‑related reactionc

Very Common

4242

5

*   No Grade 4

a    Indicates grouping of terms

b    Post‑marketing adverse reaction

c    Infusion-related reaction includes terms determined by investigators to be related to infusion, see below

 

Infusion‑related reactions

In clinical trials (monotherapy and combination treatments; N=11661530) the incidence of any grade infusion‑related reactions was 40% with the first (16 mg/kg, Week 1) infusion of DARZALEX, 2% with the Week 2 infusion, and cumulatively 4% with subsequent infusions. Less than 1% of patients had a Grade 3/4 infusion‑related reaction with the Week 2 or subsequent infusions. Grade 4 infusion reactions were reported in 2/1166 (0.2%) of patients.

The median time to onset of a reaction was 1.hours (range: 0 to 72.8 hours). The incidence of infusion modifications due to reactions was 37%. Median durations of 16 mg/kg infusions for the 1st Week, 2nd Week and subsequent infusions were approximately 7, 4 .3 and 3.4 hours respectively.

Severe infusion‑related reactions included bronchospasm, dyspnoea, laryngeal oedema, pulmonary oedema, hypoxia, and hypertension. Other adverse infusion‑related reactions included nasal congestion, cough, chills, throat irritation, vomiting and nausea (see section 4.4).

 

…….

 

Infections

In patients receiving DARZALEX combination therapy, Grade 3 or 4 infections were reported with DARZALEX combinations and background therapies (as follows:

Relapsed/refractory patient studies: DVd: 21%, Vd: 19%; DRd: 27%, Rd: 23%; D‑VMP:23%, VMP:15%; DPd: 28%)

Newly diagnosed patient studies: D‑VMP: 23%, VMP: 15%; DRd: 32%, Rd: 23%.

Pneumonia was the most commonly reported severe (Grade 3 or 4) infection across studies. In the active controlled studies, discontinuations from treatment due to infections (1-4%) Discontinuations from treatment due to infections were reported in 1% to 5% of patients. Fand fatal infections were generally infrequent and balanced between the DARZALEX containing regimens and active control arms. (<2%) in the controlled studies andFatal infections were primarily due to pneumonia and sepsis

 

5.1     Pharmacodynamic properties

 

Immunogenicity

Patients treated with daratumumab monotherapy (n=199) and combination therapy (n=412750) were evaluated for anti‑therapeutic antibody responses to daratumumab at multiple time points during treatment and up to 8 weeks following the end of treatment. Following the start of daratumumab treatment, none of the monotherapy patients and 2 of the 412 750 combination therapy patients tested.

 

Clinical efficacy and safety

Newly diagnosed multiple myeloma

Combination treatment with lenalidomide and dexamethasone in patients ineligible for autologous stem cell transplant:

Study MMY3008, an open-label, randomized, active-controlled Phase III study, compared treatment with DARZALEX 16 mg/kg in combination with lenalidomide and low-dose dexamethasone (DRd) to treatment with lenalidomide and low-dose dexamethasone (Rd) in patients with newly diagnosed multiple myeloma. Lenalidomide (25 mg once daily orally on Days 1-21 of repeated 28-day [4-week] cycles) was given with low dose oral or intravenous dexamethasone 40 mg/week (or a reduced dose of 20 mg/week for patients >75 years or body mass index [BMI] <18.5). On DARZALEX infusion days, the dexamethasone dose was given as a pre-infusion medication. Dose adjustments for lenalidomide and dexamethasone were applied according to manufacturer’s prescribing information. Treatment was continued in both arms until disease progression or unacceptable toxicity.

 

A total of 737 patients were randomized: 368 to the DRd arm and 369 to the Rd arm. The baseline demographic and disease characteristics were similar between the two treatment groups. The median age was 73 (range: 45-90) years, with 44% of the patients ≥75 years of age. The majority were white (92%), male (52%), 34% had an Eastern Cooperative Oncology Group (ECOG) performance score of 0, 49.5% had an ECOG performance score of 1 and 17% had an ECOG performance score of ≥2. Twenty-seven percent had International Staging System (ISS) Stage I, 43% had ISS Stage II and 29% had ISS Stage III disease. Efficacy was evaluated by progression free survival (PFS) based on International Myeloma Working Group (IMWG) criteria.

 

Study MMY3008 showed an improvement in Progression Free Survival (PFS) in the DRd arm as compared to the Rd arm; the median PFS had not been reached in the DRd arm and was 31.9 months in the Rd arm (hazard ratio [HR]=0.56; 95% CI: 0.43, 0.73; p<0.0001), representing 44% reduction in the risk of disease progression or death in patients treated with DRd. Results of an updated PFS analysis approximately 9 months after the original clinical cutoff, continued to show an improvement in PFS for patients in the DRd arm compared with the Rd arm. Median PFS was not reached in the DRd arm and was 33.8 months in the Rd arm (HR=0.56; 95% CI: 0.44, 0.71; p<0.0001).

 

Figure 1:         Kaplan-Meier Curve of PFS in Study MMY3008

 

 

 

Additional efficacy results from Study MMY3008 are presented in Table 6 below.

 

Table 6:           Additional efficacy results from Study MMY3008a

 

DRd (n=368)

Rd (n=369)

Overall response (sCR+CR+VGPR+PR) n(%)a

342 (92.9%)

300 (81.3%)

p-valueb

<0.0001

 

Stringent complete response (sCR)

112 (30.4%)

46 (12.5%)

Complete response (CR)

63 (17.1%)

46 (12.5%)

Very good partial response (VGPR)

117 (31.8%)

104 (28.2%)

Partial response (PR)

50 (13.6%)

104 (28.2%)

CR or better (sCR + CR)

175 (47.6%)

92 (24.9%)

p-valueb

<0.0001

 

VGPR or better (sCR + CR + VGPR)

292 (79.3%)

196 (53.1%)

p-valueb

<0.0001

 

MRD negativity ratea,c n(%)

89 (24.2%)

27 (7.3%)

95% CI (%)

(19.9%, 28.9%)

(4.9%, 10.5%)

Odds ratio with 95% CId

4.04 (2.55, 6.39)

p-valuee

<0.0001

DRd=daratumumab-lenalidomide-dexamethasone; Rd=lenalidomide-dexamethasone; MRD=minimal residual disease; CI=confidence interval

a       Based on intent-to-treat population

b       p-value from Cochran Mantel-Haenszel Chi-Squared test.

c          Based on threshold of 10-5

d          Mantel-Haenszel estimate of the odds ratio for un-stratified tables is used. An odds ratio > 1 indicates an advantage for DRd.

e       p-value from Fisherʼs exact test.

 

In responders, the median time to response was 1.05 months (range: 0.2 to 12.1 months) in the DRd group and 1.05 months (range: 0.3 to 15.3 months) in the Rd group. The median duration of response had not been reached in the DRd group and was 34.7 months (95% CI: 30.8, not estimable) in the Rd group.

 

 

5.2     Pharmacokinetic properties

 

Three Four population PK analyses were performed to describe the PK characteristics of daratumumab and to evaluate the influence of covariates on the disposition of daratumumab in patients with multiple myeloma; Analysis 1 (n=223) in patients receiving DARZALEX monotherapy while Analysis 2 (n=694), and Analysis 3 (n=352) and Analysis 4 (n=355) were conducted in patients with multiple myeloma that received daratumumab combination therapies. Analysis 2 included 694 patients (n=326 for lenalidomide-dexamethasone; n=246 for bortezomib-dexamethasone; n=99 for pomalidomide-dexamethasone; n=11 for bortezomib-melphalan-prednisone; and n=12 for bortezomib-thalidomide-dexamethasone), and Analysis 3 included 352 patients (bortezomib‑melphalan‑prednisone) and Analysis 4 included 355 patients (lenalidomide-dexamethasone).

 

Two Three additional population PK analyses (Analysis 2 and, Analysis 3 and Analysis 4) were conducted in patients with multiple myeloma that received daratumumab combination therapies. Daratumumab concentration‑time profiles were similar following the monotherapy and combination therapies. The mean estimated terminal half-life associated with linear clearance in combination therapy was approximately 2215‑23 days.

 

Based on the three four population PK analyses (Analyses 1-34) body weight was identified as a statistically significant covariate for daratumumab clearance. Therefore, body weight based dosing is an appropriate dosing strategy for the multiple myeloma patients.

 

 

Special populations

Age and gender

Based on three four individual population PK analyses (1-34) in patients receiving daratumumab monotherapy or various combination therapies (Analyses 1-34), age (range: 31‑93 years) had no clinically important effect on the PK of daratumumab, and the exposure of daratumumab was similar between younger (aged <65 years, n=515518) and older (aged ≥65 to <75 years n=562761; aged ≥75 years, n=181334) patients.

 

……

Renal impairment

No formal studies of daratumumab in patients with renal impairment have been conducted. Three Four individual population PK analyses were performed based on pre‑existing renal function data in patients receiving daratumumab monotherapy, or various combination therapies (Analyses 1-34), and included a total of 381 441 patients with normal renal function (creatinine clearance [CRCL] ≥90 mL/min), 480 621 with mild renal impairment (CRCL <90 and ≥60 mL/min), 376 523 with moderate renal impairment (CRCL <60 and ≥30 mL/min), and 20 27 with severe renal impairment or end stage renal disease (CRCL<30 mL/min). No clinically important differences in exposure to daratumumab were observed between patients with renal impairment and those with normal renal function.

 

Hepatic impairment

No formal studies of daratumumab in patients with hepatic impairment have been conducted. Changes in hepatic function are unlikely to have any effect on the elimination of daratumumab since IgG1 molecules such as daratumumab are not metabolised through hepatic pathways.

Three Four individual population PK analyses were performed in patients receiving daratumumab monotherapy or various combination therapies (Analyses 1-34), and included a total of 1081 1404 patients with normal hepatic function (total bilirubin [TB] and aspartate aminotransferase [AST] ≤ upper limit of normal [ULN]), 159 189 with mild hepatic impairment (TB 1.0 x to 1.5 x ULN or AST >ULN) and patients with moderate (TB > 1.5 x to 3.0 x ULN; n=67), or severe (TB > 3.0 x ULN; n=1) hepatic impairment. No clinically important differences in the exposure to daratumumab were observed between patients with hepatic impairment and those with normal hepatic function.

 

Race

Based on three four individual population PK analyses in patients receiving either daratumumab monotherapy or various combination therapies (Analyses 1-34), the exposure to daratumumab was similar between white (n=10461371) and non‑white subjects (n=212242).

 

Updated on 02 July 2019

File name

IRE -C08-PIL-Darzalex- Jun 2019-CLEAN.pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 02 July 2019

File name

C09_SmPC-Darzalex-28 June 2019_Clean.pdf

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.4     Special warnings and precautions for use

 

 

Hepatitis B virus (HBV) Reactivation

Hepatitis B virus reactivation, in some cases fatal, has been reported in patients treated with DARZALEX. HBV screening should be performed in all patients before initiation of treatment with DARZALEX.

For patients with evidence of positive HBV serology, monitor for clinical and laboratory signs of HBV reactivation during, and for at least six months following the end of DARZALEX treatment. Manage patients according to current clinical guidelines. Consider consulting a hepatitis disease expert as clinically indicated.

In patients who develop reactivation of HBV while on DARZALEX, suspend treatment with DARZALEX and institute appropriate treatment. Resumption of DARZALEX treatment in patients whose HBV reactivation is adequately controlled should be discussed with physicians with expertise in managing HBV.

 

 

4.8     Undesirable effects

 

 

Infections and infestations

Pneumoniaa

Very Common

16

11

Upper respiratory tract infectiona

50

5

Influenza

Common

4

1*

Hepatitis B Virus reactivationb

Uncommon

-

-

Updated on 21 December 2018

File name

IRE C07-PIL-Darzalex-Dec 2018-clean.pdf

Reasons for updating

  • Change to section 3 - dose and frequency
  • Change to section 6 - date of revision

Updated on 21 December 2018

File name

C08_SmPC-Darzalex-18 December 2018-clean.pdf

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

 

 

 

 

 

 

 

 

 

 

 

Updated on 10 December 2018

File name

IRE C06-PIL-Darzalex-Nov 2018-clean.pdf

Reasons for updating

  • Change to section 6 - what the product looks like and pack contents
  • Change to section 6 - date of revision

Updated on 10 December 2018

File name

C07_SmPC-Darzalex-30 November 2018-Clean.pdf

Reasons for updating

  • Change to section 6.5 - Nature and contents of container
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

6.5     Nature and contents of container

 

5 mL concentrate in a Type 1 glass vial with an elastomeric closure and an aluminium seal with a flip‑off button containing 100 mg of daratumumab. Pack size of 1 vial.

20 mL concentrate in a Type 1 glass vial with an elastomeric closure and an aluminium seal with a flip‑off button containing 400 mg of daratumumab. Pack size of 1 vial.

DARZALEX is also supplied as an initiation pack containing 11  vials : (6 x 5 mL vials + 5 x 20 mL vials).

 

8.       MARKETING AUTHORISATION NUMBER(S)

 

EU/1/16/1101/001

EU/1/16/1101/002

EU/1/16/1101/003

 

 

 

Updated on 30 October 2018

File name

IRE C05-PIL-Darzalex-Oct 2018-CLEAN.pdf

Reasons for updating

  • Change to section 6 - date of revision
  • Change of distributor details

Updated on 04 September 2018

File name

C04-PIL-Darzalex-Aug 2018-Clean.pdf

Reasons for updating

  • Change to section 1 - what the product is used for
  • Change to section 3 - duration of treatment
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 04 September 2018

File name

C06_SmPC-Darzalex-31 August 2018.pdf

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Addition 4.2       Posology and method of administrationof a new indication.

DARZALEX is indicated:

  • in combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

4.2       Posology and method of administration

This section has been extensively revised

 

 

Section 4.8

 

 

Added. very common , hu ypertension  Common: pulmonary oedema

 

Section 5.1 and 5.2 updated

Updated on 28 June 2018

File name

C05_SmPC_Darzalex_03_May_18-CLEAN_approved.docx

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Unforunately the is section will not allow all the changes to be published. Please conatc Janssen-Cilag Ltd medical informatiomn if you would like the details of the changes

Updated on 28 June 2018

File name

C03-PIL-Darzalex- TC- May 2018_Clean.pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision
  • Change to information for healthcare professionals

Updated on 16 May 2018

File name

C04_SmPC_Darzalex_15_Mar_18_Clean.docx

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

 

 

Updated on 16 August 2017

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 16 August 2017

Reasons for updating

  • Change to section 6.3 - Shelf life
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

 

6.3     Shelf life

 

Unopened vials

18  24 months

Updated on 16 August 2017

Reasons for updating

  • Change to section 6.3 - Shelf life
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

 

6.3     Shelf life

 

Unopened vials

18  24 months

Updated on 03 May 2017

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.1       Therapeutic indications

DARZALEX is indicated:

·                as monotherapy is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.

·                in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone,for the treatment of adult patients with multiple myeloma who have received at least one prior therapy

 

 

4.2          Posology and method of administration

 

Dose

Standard dosing for monotherapy and in combination with lenalidomide (4week cycle regimen):

The recommended dose is DARZALEX 16 mg/kg body weight administered as an intravenous infusion according to the following dosing schedule in Table 1.:

 

 

Table 1:         Standard DARZALEX dosing schedule for monotherapy and in combination with lenalidomide (4-week cycle dosing regimen)

Weeks

Schedule

Weeks 1 to 8

weekly (total of 8 doses)

Weeks 9 to 24a

every two weeks (total of 8 doses)

Week 25 onwards until disease progressionb

every four weeks

a     First dose of the every-2-week dosing schedule is given at week 9

b     First dose of the every-4-week dosing schedule is given at week 25

 

 

For dose and schedule of medicinal products administered with DARZALEX, see section 5.1 and the corresponding Summary of Product Characteristics.

 

Modified dosing schedule in combination with bortezomib (3week cycle regimen):

The recommended dose is DARZALEX 16 mg/kg body weight administered as an intravenous infusion according to the following dosing schedule in Table 2.

 

Table 2:         Modified DARZALEX dosing schedule in combination with bortezomib (3-week cycle dosing regimen)

Weeks